Solventum Corporation (NYSE:SOLV) Stock Has Consensus Price Target of $92.80 According to Brokerages

Solventum Corporation (NYSE:SOLV) has been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $87.55.

SOLV has been the topic of a number of recent analyst reports. Wedbush boosted their price target on shares of Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Mizuho set a $113.00 price objective on shares of Solventum in a research note on Thursday, August 6th. Benchmark reissued a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Canadian Imperial Bank of Commerce set a $35.00 target price on Solventum in a research report on Wednesday. Finally, Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, September 12th.

Solventum Stock Down 1.5%

SOLV opened at $81.75 on Thursday. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a market cap of $13.92 billion, a P/E ratio of 9.99, a P/E/G ratio of 1.31 and a beta of 0.63. The stock’s 50 day moving average price is $88.36 and its 200 day moving average price is $78.55.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the firm posted $1.69 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts predict that Solventum will post 7.21 earnings per share for the current year.

Institutional Investors Weigh In On Solventum

Hedge funds and other institutional investors have recently bought and sold shares of the business. Laurel Wealth Advisors LLC acquired a new position in Solventum during the third quarter worth $29,000. Clearstead Trust LLC lifted its position in shares of Solventum by 61.0% in the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after buying an additional 150 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Solventum by 80.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 429 shares of the company’s stock worth $34,000 after buying an additional 191 shares during the last quarter. JNBA Financial Advisors boosted its stake in shares of Solventum by 71.9% during the 2nd quarter. JNBA Financial Advisors now owns 507 shares of the company’s stock worth $39,000 after acquiring an additional 212 shares in the last quarter. Finally, Ameritas Advisory Services LLC bought a new stake in shares of Solventum during the 2nd quarter worth about $47,000.

About Solventum

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.